ProtecTion from overtreatment - does a randomised trial finally answer the key question in localised prostate cancer?

For the first time we now have a randomised trial comparing active monitoring, surgery and radiation therapy for the management of localised prostate cancer and the investigators are to be congratulated on this highly anticipated landmark study - the Prostate testing for cancer and Treatment (ProtecT) trial[1]. Comparing 545 patients randomised to active monitoring, 553 to radical prostatectomy, and 545 to radiotherapy, at a median follow-up of 10 years the study reports no significant difference in prostate-cancer specific or overall survival amongst the three groups[1]. This article is protected by copyright. All rights reserved.

BJU international. 2016 Jan 08 [Epub ahead of print]

Luke L Wang, Christopher J D Wallis, Niranjan Sathianathen, Nathan Lawrentschuk, Declan G Murphy, Robert Nam, Daniel Moon

Australian Urology Associates, Malvern, Victoria, Australia., Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada., Division of Cancer Surgery, University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe